Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?

Szczegóły
Pełny tekst

Tytuł:: Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?
Autorzy:: Gnanapragasam VJ; Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK.; Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK.
Barrett T; Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.
Pacey S; Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK.
Warren A; Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK.; Department of Pathology, Addenbrookes Hospital, Cambridge, UK.
Źródło:: BJU international [BJU Int] 2021 Jun; Vol. 127 (6), pp. 628-629. Date of Electronic Publication: 2021 Apr 16.
Typ publikacji:: Letter
Język:: English
Imprint Name(s):: Original Publication: Oxford, UK : Blackwell Science, c1999-
MeSH Terms:: Watchful Waiting*
Prostatic Neoplasms/*therapy
Humans ; Male
References:: National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management. NICE guideline [NG131]. Available at: https://www.nice.org.uk/guidance/ng131. Accessed March 2021.
Gnanapragasam VJ, Barrett T, Thankapannair V et al. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU Int 2019; 124: 758-67.
Thurtle D, Barrett T, Thankappan-Nair V et al. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int 2018; 122: 59-65.
Moore CM, Giganti F, Albertsen P et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE Recommendations-A Report of a European School of Oncology Task Force. Eur Urol 2017; 71: 648-55.
Norris JM, Simpson BS, Freeman A, Kirkham A, Whitaker HC, Emberton M. Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: a cross-disciplinary translational hypothesis. FASEB J 2020; 34: 14150-9.
Klotz L, Grudén S, Axén N et al. Liproca depot: a new antiandrogen treatment for active surveillance patients. Eur Urol Focus 2021; S2405-4569:00046-8. [Epub ahead of print]. https://doi.org/10.1016/j.euf.2021.02.003.
Caglic I, Sushentsev N, Gnanapragasam VJ et al. MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol 2020 [Epub ahead of print]. https://doi.org/10.1007/s00330-020-07336-0.
Entry Date(s):: Date Created: 20210328 Date Completed: 20211007 Latest Revision: 20211007
Update Code:: 20240105
DOI:: 10.1111/bju.15409
PMID:: 33774889
: Opinia redakcyjna

Pełny tekst

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja